Search

Your search keyword '"Schou, Magnus"' showing total 413 results

Search Constraints

Start Over You searched for: Author "Schou, Magnus" Remove constraint Author: "Schou, Magnus"
413 results on '"Schou, Magnus"'

Search Results

1. Data from Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1

2. Supplementary Data 1 from Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1

3. Radiosynthesis and Evaluation of 11C-Labeled Isoindolone-Based Positive Allosteric Modulators for Positron Emission Tomography Imaging of Metabotropic Glutamate Receptor 2.

4. Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood–Brain Barrier: The Discovery of AZD1390

8. Validation of a good manufacturing practice procedure for the production of [11C]AZD4747, a CNS penetrant KRASG12c inhibitor.

9. Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1

10. Discovery, preclinical validation and early human imaging with [11C]AZ14193391 – the first blood-brain barrier permeable and subtype selective PARP1 PET radioligand

11. [11C]Vercirnon - a candidate PET radioligand for the CCR9 chemokine receptor

15. Quantification and reliability of [11C]VC - 002 binding to muscarinic acetylcholine receptors in the human lung — a test-retest PET study in control subjects

18. Supplementary Data from Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs

19. Figure S1 from Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs

20. Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non‐small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study

21. O-69 - Discovery, preclinical validation and early human imaging with [11C]AZ14193391 – the first blood-brain barrier permeable and subtype selective PARP1 PET radioligand

25. Proof of lung muscarinic receptor occupancy by tiotropium: Translational Positron Emission Tomography studies in non-human primates and humans

27. Isotopic Radiolabeling of Crizotinib with Fluorine-18 for In Vivo Pet Imaging

30. DDDR-01. AZD9574 IS A NOVEL, BRAIN PENETRANT PARP-1 SELECTIVE INHIBITOR WITH ACTIVITY IN AN INTRACRANIAL XENOGRAFT MODEL OF TRIPLE NEGATIVE BREAST CARCINOMA WITH HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY

31. Lung muscarinic receptor occupancy by tiotropium: translational Positron Emission Tomography studies in non-human primates and humans

33. Reactive Palladium–Ligand Complexes for 11 C-Carbonylation at Ambient Pressure: A Breakthrough in Carbon-11 Chemistry.

34. 18th European Symposium on Radiopharmacy and Radiopharmaceuticals: Salzburg, Austria. 7-10 April 2016

37. Abstract 6302: Structure-based and property-based drug design of AZD9574, a CNS penetrant PARP1 selective inhibitor and trapper

39. Abstract 5076: Evaluation of the CNS penetration of a next generation PARP inhibitor, AZD9574, in cynomolgus monkey using positron emission tomography

45. Sa2018 FIRST-TIME-IN-HUMAN VISUALISATION OF CCR9 EXPRESSION IN THE GUT BY POSITRON EMISSION TOMOGRAPHY

46. Lung muscarinic receptor occupancy by tiotropium: translational PET studies in non-human primates and humans

48. Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [11 C] PBR28 and Machine Learning Analysis

Catalog

Books, media, physical & digital resources